Aurinia Pharmaceuticals Inc. (AUPH)
Levi & Korsinsky, LLP announces that a AUPH class action lawsuit has been filed on behalf of investors who purchased Aurinia Pharmaceuticals Inc. (AUPH) securities between May 7, 2021 and February 25, 2022. For more on the AUPH Lawsuit please contact us today.
According to the Aurinia Pharmaceuticals Inc. lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:
(i) Aurinia was experiencing declining revenues; (ii) Aurinia’s 2022 sales outlook for the Company’s only product which it offers for the treatment of adult patients with active lupus nephritis, LUPKYNIS, would fall well short of expectations; (iii) accordingly, the Company had significantly overstated LUPKYNIS’s commercial prospects; (iv) as a result, the Company had overstated its financial position and/or prospects for 2022; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Aurinia Pharmaceuticals Inc. you have until June 14, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Aurinia Pharmaceuticals Inc. Class Action Lawsuit
Aurinia Pharmaceuticals Inc. Lawsuit
AUPH Class Action Lawsuit
Aurinia Pharmaceuticals Inc. (AUPH) Class Action Lawsuit